Henry Schein (NASDAQ:HSIC) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Henry Schein (NASDAQ:HSIC) posted its quarterly earnings results on Tuesday. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.11, Zacks reports. The firm had revenue of $3.34 billion during the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein updated its FY 2025 guidance to 4.880-4.960 EPS.

Henry Schein Stock Up 0.4%

HSIC traded up $0.27 during midday trading on Wednesday, hitting $71.88. 784,274 shares of the company’s stock traded hands, compared to its average volume of 1,718,469. Henry Schein has a one year low of $60.56 and a one year high of $82.49. The company has a market cap of $8.72 billion, a PE ratio of 23.19, a price-to-earnings-growth ratio of 2.06 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The stock’s fifty day simple moving average is $66.17 and its 200-day simple moving average is $68.61.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HSIC. Weiss Ratings reissued a “hold (c-)” rating on shares of Henry Schein in a research note on Friday, October 31st. Evercore ISI lifted their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wells Fargo & Company lifted their target price on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday. Barrington Research set a $79.00 price target on shares of Henry Schein in a report on Wednesday. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $75.00 price objective (down previously from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Five research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Henry Schein currently has an average rating of “Hold” and a consensus target price of $77.42.

Institutional Investors Weigh In On Henry Schein

Large investors have recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its position in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Henry Schein by 39.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 408,360 shares of the company’s stock valued at $29,831,000 after purchasing an additional 114,750 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Henry Schein by 0.8% during the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after buying an additional 1,669 shares in the last quarter. Finally, Zuckerman Investment Group LLC raised its stake in Henry Schein by 3.8% in the second quarter. Zuckerman Investment Group LLC now owns 209,299 shares of the company’s stock valued at $15,289,000 after purchasing an additional 7,660 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.